Luo XX, Du YX, Zhang QQ, Zhang L, Zeng SY, Yu ZH, Shen P, Feng ZQ. Cetuximab combined with chemotherapy for simultaneous esophageal squamous cell carcinoma and colon adenocarcinoma: A case report. World J Clin Cases 2024; 12(15): 2649-2654 [PMID: 38817214 DOI: 10.12998/wjcc.v12.i15.2649]
Corresponding Author of This Article
Zheng-Quan Feng, MD, PhD, Chief Physician, Director, Department of Oncology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Xihu District, Hangzhou 310012, Zhejiang Province, China. fzhq213@aliyun.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 26, 2024; 12(15): 2649-2654 Published online May 26, 2024. doi: 10.12998/wjcc.v12.i15.2649
Cetuximab combined with chemotherapy for simultaneous esophageal squamous cell carcinoma and colon adenocarcinoma: A case report
Xin-Xin Luo, Yu-Xuan Du, Qi-Qing Zhang, Lin Zhang, Shu-Ying Zeng, Zhi-Hong Yu, Peng Shen, Zheng-Quan Feng
Xin-Xin Luo, Lin Zhang, Shu-Ying Zeng, The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang Province, China
Yu-Xuan Du, Qi-Qing Zhang, Zhi-Hong Yu, Zheng-Quan Feng, Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang Province, China
Peng Shen, Department of Medical Oncology, The First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Author contributions: Luo XX, Zhang L and Zeng SY contributed to conceptualization, methodology, data curation and analysis, writing (original draft), and visualization; Luo XX, Du YX, Zhang QQ and Yu ZH contributed to data acquisition; Shen P and Feng ZQ contributed to writing (review and editing); Yu ZH, Shen P and Feng ZQ contributed to supervision. All authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All authors declare no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Zheng-Quan Feng, MD, PhD, Chief Physician, Director, Department of Oncology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Xihu District, Hangzhou 310012, Zhejiang Province, China. fzhq213@aliyun.com
Received: February 16, 2024 Revised: March 15, 2024 Accepted: April 9, 2024 Published online: May 26, 2024 Processing time: 87 Days and 18.6 Hours
Abstract
BACKGROUND
Multiple primary carcinomas (MPCs) are defined as two or more independent primary cancers that occur simultaneously or sequentially in the same individual. Synchronous MPCs are rarer than solitary cancers or metachronous MPCs. Accurate diagnoses of synchronous MPCs and the choice of treatment are critical for successful outcomes in these cases.
CASE SUMMARY
A 64-year-old patient presented with dysphagia, without obvious cause. A diagnosis of synchronous esophageal squamous cell carcinoma and colon adenocarcinoma with liver metastasis was confirmed based on examination and laboratory results. After multi-disciplinary consultations, combination chemotherapy (a 3-wk cycle with oxaliplatin 212 mg administered on day 1 and capecitabine 1.5 g twice daily on days 1-14) and esophageal cancer radiotherapy were initiated. Based on the results of genetic testing, we switched to a regimen of leucovorin + fluorouracil + oxaliplatin and cetuximab regimen for 8 cycles. Subsequently, capecitabine and bevacizumab were administered until the most recent follow-up, at which the tumor remained stable.
CONCLUSION
Successful cetuximab chemotherapy treatment provides a reference for the non-operative and homogeneous treatment of different pathological types of synchronous MCPs.
Core Tip: We report a case of a 64-year-old patient diagnosed with synchronous esophageal squamous cell carcinoma and colon adenocarcinoma with liver metastasis. After multi-disciplinary consultations, oxaliplatin + capecitabine chemotherapy and esophageal cancer radiotherapy were initiated. Based on genetic testing, treatment was switched to a regimen of leucovorin + fluorouracil + oxaliplatin and cetuximab for 8 cycles. Subsequently, capecitabine and bevacizumab were administered, and the tumor was stable at the most recent follow-up. This case demonstrates successful treatment of dual primary digestive tract tumors of differing pathological types using the same regimen, which supports non-surgical, simultaneous treatment for synchronous multiple primary cancers.
